A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy

A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy

DSpace/Manakin Repository

A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy

dc.contributor.author	Tseng-Rogenski, Stephanie S
dc.contributor.author	Escara-Wilke, June F
dc.contributor.author	Neeley, Yilin C
dc.contributor.author	Imperiale, Michael J
dc.contributor.author	Arredouani, Mohamed Simo
dc.contributor.author	Sanda, Martin George
dc.date.accessioned	2010-12-22T16:08:20Z
dc.date.issued	2008
dc.identifier.citation	Tseng-Rogenski, Stephanie S., Mohamed S. Arredouani, June F. Escara-Wilke, Yilin C. Neeley, Michael J. Imperiale, and Martin G. Sanda. 2008. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Design, Development and Therapy 2: 17-24.	en_US
dc.identifier.issn	1177-8881	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:4633209
dc.description.abstract	Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Dove Medical Press	en_US
dc.relation.isversionof	http://www.dovepress.com/a-safety-modified-sv40-tag-developed-for-human-cancer-immunotherapy-peer-reviewed-article-DDDT-recommendation1	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761181/pdf/	en_US
dash.license	LAA
dc.subject	modified SV-40 T antigen	en_US
dc.subject	recombinant vaccinia	en_US
dc.subject	cancer immunotherapy	en_US
dc.title	A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Drug Design Development and Therapy	en_US
dash.depositing.author	Arredouani, Mohamed Simo
dc.date.available	2010-12-22T16:08:20Z
dash.affiliation.other	HMS^Surgery- Beth Israel-Deaconess	en_US